Edition:
India

Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China


Monday, 11 Dec 2017 

Dec 11 (Reuters) - Ardelyx Inc ::Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China.Ardelyx - under terms of agreement, Ardelyx will receive upfront payment of $12 million, is eligible to receive additional milestones of up to $113 million.Ardelyx Inc - Fosun Pharma will have exclusive rights to market and sell Tenapanor in China.Ardelyx - under terms of agreement, co will receive tiered royalty payments on net sales from Tenapanor ranging from mid-teens to 20 percent.Ardelyx Inc - agreement also provides Fosun Pharma rights to commercialize Tenapanor for other indications for which it is approved in United States. 

Company Quote

6.02
0.21 +3.61%
2:29am IST